Objective: To examine the effectiveness of screening for trisomy 21 by a combination of maternal age, fetal nuchal translucency (NT) thickness and maternal serum biochemistry using free 尾-human chorionic gonadotropin (hCG) and pregnancy-associated plasma protein-A (PAPP-A) at 11-14 weeks of ...
NB and NT can be used as two independent ultrasononographic factors during screening for Trisomy 21. Nasal bone length increases linearly with biacrominal diameter in the first trimester. 展开 关键词: 11 to 13+6 weeks of gestation ultrasonographic screening Trisomy 21 ...
In the present study at 11–14 weeks the femur length was below the 5th centile of the normal range in only 9% of trisomy 21 fetuses. An additional problem with early gestation is the poor reproducibility of the measurements. Thus, at 11–14 weeks the mean difference between paired ...
In 47,XXX, there is a wide variation in IQ with the normal curve shifted to the left with the mean FSIQ at 85-90. The majority of females with 47,XXX have a FSIQ in the normal range, and many are above average compared to the general population. However, due to the shift of the...
In 47,XXX, there is a wide variation in IQ with the normal curve shifted to the left with the mean FSIQ at 85-90. The majority of females with 47,XXX have a FSIQ in the normal range, and many are above average compared to the general population. However, due to the shift of the...
In 47,XXX, there is a wide variation in IQ with the normal curve shifted to the left with the mean FSIQ at 85-90. The majority of females with 47,XXX have a FSIQ in the normal range, and many are above average compared to the general population. However, due to the shift of the...
Her parents' karyotypes were normal. We supposed that the marker chromosome was derived from two chromosomes 21. The red blood ceils SODI activity was within normal range, so the marker chromosome did not contain the locus for SODI gene. We con- cluded that her karyotype was 47,XX,+psu...
OP02.07: The NTplus screening model for trisomy 21 ‐ a modified integrated testNo Abstract.doi:10.1002/uog.6661O. HabayebFetal Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United KingdomS. GoodburnClinical Biochemistry, Cambridge University Hospitals NHS Foundation Trust, ...
OP02.07: The NTplus screening model for trisomy 21 - a modified integrated testdoi:10.1002/uog.6661O. HabayebFetal MedicineS. GoodburnFetal MedicineT. ChudleighFetal MedicineJ. BrockelsbyFetal MedicineH. Missfelder-LobosFetal MedicineG. Hackett...
OP02.07: The NTplus screening model for trisomy 21 - a modified integrated testdoi:10.1002/uog.6661O. HabayebS. GoodburnT. ChudleighJ. BrockelsbyH. Missfelder-LobosG. HackettC. LeesJohn Wiley & Sons, Ltd.